BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Hypertension clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hypertension: 364 (213 sponsors; 76 newly posted in the last 180 days, 20 stopped in the last 180 days; 40 new-entrant sponsors). Momentum score 16.3, rank 39 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 40, Phase 2 66, Phase 3 65, Phase 4 13, N/A 179.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Insmed Incorporated INSM | 4 | P3 4 | 0 | 1 |
| AstraZeneca AZN | 6 | P3 3, NA 2, P2 1 | 1 | 2 |
| Liquidia Technologies, Inc. LQDA | 5 | P3 3, P4 1, NA 1 | 1 | 1 |
| Actelion | 4 | P3 3, P2 1 | 0 | 1 |
| Eli Lilly and Company LLY | 4 | P3 3, P2 1 | 1 | 1 |
| Tenax Therapeutics, Inc. TENX | 3 | P3 3 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 9 | P2 5, P4 2, P3 2 | 4 | 0 |
| United Therapeutics UTHR | 6 | P3 2, P2 1, NA 2, P4 1 | 2 | 2 |
| SpyGlass Pharma, Inc. SGP | 5 | P1 1, NA 1, P3 2, P2 1 | 1 | 1 |
| Ablative Solutions, Inc. | 2 | P3 2 | 0 | 0 |
| Inhibikase Therapeutics IKT | 2 | P3 2 | 1 | 0 |
| Shandong Suncadia Medicine Co., Ltd. | 2 | P3 2 | 1 | 0 |
| Boryung Pharmaceutical Co., Ltd | 9 | P1 4, NA 3, P2 1, P3 1 | 1 | 2 |
| Glaukos Corporation GKOS | 7 | P4 2, P2 1, NA 3, P3 1 | 1 | 2 |
| Addpharma Inc. | 4 | P1 3, P3 1 | 0 | 0 |
| AOP Orphan Pharmaceuticals AG | 4 | NA 2, P4 1, P3 1 | 1 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 4 | P1 2, P2 1, P3 1 | 1 | 1 |
| AbbVie ABBV | 3 | P4 1, P2 1, P3 1 | 0 | 0 |
| Pulmovant, Inc. | 3 | P2 2, P3 1 | 1 | 1 |
| Alnylam Pharmaceuticals ALNY | 2 | P2 1, P3 1 | 0 | 0 |
| Bayer | 2 | NA 1, P3 1 | 0 | 0 |
| CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. new entrant | 2 | P2 1, P3 1 | 2 | 1 |
| Hanmi Pharmaceutical Company Limited HAFC new entrant | 2 | P3 1, NA 1 | 2 | 0 |
| Huons Co., Ltd. | 2 | P1 1, P3 1 | 1 | 1 |
| Pulnovo Medical (Wuxi) Co., Ltd. | 2 | P3 1, NA 1 | 0 | 0 |
New-entrant sponsors: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Hanmi Pharmaceutical Company Limited.
Recently stopped trials
- NCT02709031 Navitas Pharma - withdrawn: The study did not receive funding. Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
- NCT04816604 Gossamer Bio USA, Inc. - terminated: Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no l Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
- NCT04968184 Novo Nordisk A/S - terminated: Interim futility analysis showed primary endpoint not achieved Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
- NCT07073820 Pfizer - terminated: The study terminated due to a business decision and was not based on any safety and/or efficacy concerns. A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P
- NCT06608472 Eurofarma Laboratorios S.A. - withdrawn: Strategic change in development priorities. Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
- NCT06518915 neuroloop GmbH - terminated: Terminated following a device deficiency in 1 subject. Benefit-risk and development assessments did not support continuation within the plan Baroloop Multicenter Trial (Baroloop MCT)
- NCT06577857 Sanoculis Ltd - terminated: The study was terminated following completion of the Week 24 visit. The Week 30 follow-up visit was canceled due to internal company reasons Inferonasal MIMSĀ® Procedure: Long-Term Follow-Up Extension Study
- NCT05516498 AstraZeneca - terminated: The study was ended earlier than planned due to a sponsor decision. Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
- NCT07223502 Sarfez Pharmaceuticals, Inc. - withdrawn: No recruitment A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide
- NCT01065454 Bayer - terminated: The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systol
- NCT06465537 Shanghai BDgene Co., Ltd. - suspended: Per the requirement of China regulation. CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
- NCT03686657 ARKAY Therapeutics - withdrawn: Clinical stage asset and the sponsorship have been acquired by Myopharm Limited. Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
- NCT04084678 United Therapeutics - terminated: Sponsor decision Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
- NCT05975905 Keros Therapeutics, Inc. - terminated: The study was voluntarily terminated early, following a safety review and observation of pericardial effusions. A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants W
- NCT04365868 Galectin Therapeutics Inc. - terminated: Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons. Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | United Therapeutics UTHR | NCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | enrolling by invitation | 1000 |
| 2026-12 est. | P3 | Boryung Pharmaceutical Co., Ltd | NCT06220773 A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | Essential Hypertension; Type 2 Diabetes Mellitus | recruiting | 276 |
| 2026-12 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07297797 Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension | Mild to Moderate Hypertension | active not recruiting | 238 |
| 2026-12 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT07489612 QLS1410 in Participants With Uncontrolled Hypertension | Hypertension (HTN) | enrolling by invitation | 260 |
| 2026-12 est. | P2 | Kardigan, Inc. KARD | NCT07511361 Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | Hypertension; Acute Severe Hypertension; Hypertensive Emergency; Hypertensive Urgency | recruiting | 140 |
| 2026-12-10 est. | P2 | AstraZeneca AZN | NCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Ki | Chronic Kidney Disease and Hypertension | active not recruiting | 222 |
| 2027-01 est. | P1/P2 | EyeD Pharma | NCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery | Glaucoma; Ocular Hypertension | recruiting | 42 |
| 2027-01-31 est. | P3 | Actelion | NCT05179876 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | Hypertension, Pulmonary | recruiting | 280 |
| 2027-01-31 est. | P2 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT07940075 SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension . | Mild to Moderate Primary Hypertension | recruiting | 360 |
| 2027-02-01 est. | P2 | Boryung Pharmaceutical Co., Ltd | NCT07373613 A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | Essential Hypertension | not yet recruiting | 330 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-12-22 | PDUFA date (company-disclosed) | pending | Mineralys Therapeutics, Inc. MLYS | lorundrostat | PDUFA December 22, 2026 - Mineralys Therapeutics, Inc. (lorundrostat) |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-15 est. | P2 | PolyActiva Pty Ltd | NCT06964191 Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | Glaucoma, Open-Angle; Ocular Hypertension | active not recruiting | 75 |
| 2026-11-04 | P3 | THPharm Corp. | NCT06647745 A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP | Type 2 Diabetes; Hypertension | active not recruiting | 222 |
| 2026-10-30 est. | P2 | Vincentage Pharma Co., Ltd | NCT07360275 A Study of VCT220 in Participants With Hypertension and Obesity or Overweight | Hypertension | active not recruiting | 160 |
| 2026-10 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | Hypertension; Uncontrolled Hypertension | recruiting | 240 |
| 2026-09-17 | P3 | Sarfez Pharmaceuticals, Inc. | NCT07223502 A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hyp | Hypertension (HTN) | withdrawn | |
| 2026-09-17 | P2 | Novartis Pharmaceuticals NVS | NCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | Hypertension | active not recruiting | 396 |
| 2026-09-15 | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07835971 A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension | Hypertension | active not recruiting | 319 |
| 2026-08-31 est. | P3 | Santen Pharmaceutical Co., Ltd. | NCT06666855 A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Open Angle Glaucoma; Ocular Hypertension | active not recruiting | 345 |
| 2026-07-22 | P2/P3 | Qlaris Bio, Inc. | NCT07354516 Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension | OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension | completed | 64 |
| 2026-07-02 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07790120 A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hype | Uncontrolled Hypertension; Resistant Hypertension | completed | 256 |
| 2026-06-19 | P3 | AbbVie ABBV | NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | Open-Angle Glaucoma; Ocular Hypertension | completed | 455 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hypertension"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.